IDO1 and cancer: However, immune-competent subtypes in several cancer types had relatively lower expressions than immune-deficient subtypes, particularly VTCN1 in GBM and LAG3 and IDO1 in PCPG were significantly elevated in immune-deficient subtypes (Fig. 4c).